Novavax shareholders show strong dissent at AGM, opposing executive pay and board nominees.

At Novavax's June 18, 2026 Annual Meeting, significant shareholder dissatisfaction was evident as nearly half opposed the executive compensation package and 38-41% voted against re-electing three board members. Shah Capital, the largest shareholder, criticized the leadership for poor performance, high costs, and weak execution, calling for urgent changes including board size reduction, cost cuts, and share buybacks. This vote signals a strong demand for improved governance and strategic focus to restore shareholder value and credibility.